featured
Urology PracticeChanger in 2015: Maintenance BCG
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized South West Oncology Group study. J. Urol. 2000;163(4):1124-1129.
- Ehdaie B, Sylvester R, Herr HW. Maintenance bacillus Calmette-Guérin treatment of non-muscle-invasive bladder cancer: a critical evaluation of the evidence. Eur Urol. 2013;64(4):579-585.
- Martínez-Piñeiro L, Portillo JA, Fernández JM, et al. Maintenance Therapy With 3-Monthly Bacillus Calmette-Guérin for 3 Years Is Not Superior to Standard Induction Therapy in High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma: Final Results of Randomised CUETO Study 98013. Eur Urol. 2015;68(2)256-262.
- Pfister C, Kerkeni W, Rigaud J, et al. Efficacy and Tolerance of One-Third Full Dose Bacillus Calmette-Guérin Maintenance Therapy Every 3 Months or 6 Months: Two-Year Results of URO-BCG-4 Multicenter Study. Int J Urol. 2015;22(1):53-60.
Disclosure statements are available on the authors' profiles: